Evidence map›Paper›PMID 41001391›Full record

ArticleFrontiers in medicine2025

Dupilumab relieves pruritus both in uremic pruritus and in atopic dermatitis with chronic kidney disease: a retrospective real-world study.

Qian Wang, Ge Yang, Xiyuan Zhou, Xiang Zhong, Jie Liu, Lixia Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qian Wang *Institute of Dermatology and Venereology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Ge Yang *Institute of Dermatology and Venereology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiyuan ZhouInstitute of Dermatology and Venereology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiang ZhongDepartment of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu, China.
Jie LiuDepartment of Pharmacy, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lixia ZhangInstitute of Dermatology and Venereology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Treatment methods for pruritus in patients with chronic kidney disease (CKD) are lacking. Exploring the therapeutic potential of dupilumab in alleviating pruritus in CKD patients has good clinical value. Objectives: This retrospective study aims to analyze the effectiveness and safety of dupilumab in atopic dermatitis (AD) patients with CKD and uremic pruritus (UP) patients. Methods: Demographic and clinical data from AD patients with CKD stages 3-5 and UP patients who received dupilumab treatment were retrospectively analyzed. Improvements in pruritus were assessed via Peak Pruritus Numerical Rating Scale (PP-NRS) and 5-D itch scale (5-D IS) at weeks 2, 4, 12, and 16. Eczema Area and Severity Index (EASI) and Atopic Dermatitis Control Tool (ADCT) scores were also recorded at week 16 in AD patients with CKD. Safety during treatment was observed. Results: After dupilumab treatment, the PP-NRS and 5D-IS scores of 12 AD patients with CKD and 10 UP patients were significantly decreased. The percentages of UP patients who achieved PP-NRS ≥ 4-point improvement and 5D-IS ≤ 10-point at week 4, 12, and 16 did not significantly differ from those of AD patients with CKD ( Conclusion: Dupilumab safely and effectively reduced pruritus in UP patients in the short term and achieved a comparable anti-pruritus effect to AD patients with CKD.

Indexed as

atopic dermatitischronic kidney diseasedupilumabeffectivenesspruritus

Identifiers

PMID41001391
PMCPMC12457180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.